Hoyek, C., Pirozzi, A., Zheng, B., Lida, N., Ramaker, R., Abidoye, S., … Bekaii-Saab, T. (2025). CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC). J Natl Compr Canc Netw, 23(3.5). https://doi.org/10.6004/jnccn.2024.7161

Hoyek, Celine, Angelo Pirozzi, Binbin Zheng, Naoko Lida, Ryne Ramaker, Seyi Abidoye, Cody Eslinger, et al. “CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC).” J Natl Compr Canc Netw 23, no. 3.5 (March 28, 2025). https://doi.org/10.6004/jnccn.2024.7161.

Hoyek C, Pirozzi A, Zheng B, Lida N, Ramaker R, Abidoye S, et al. CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC). J Natl Compr Canc Netw. 2025 Mar 28;23(3.5).

Hoyek, Celine, et al. “CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC).” J Natl Compr Canc Netw, vol. 23, no. 3.5, Mar. 2025. Pubmed, doi:10.6004/jnccn.2024.7161.

Hoyek C, Pirozzi A, Zheng B, Lida N, Ramaker R, Abidoye S, Eslinger C, Shibuki T, Wu CSY, Sonbol MB, Ahn DH, Borad M, Ikeda M, Nakamura Y, Rimassa L, Yoshino T, Strickler J, Bekaii-Saab T. CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC). J Natl Compr Canc Netw. 2025 Mar 28;23(3.5).